tiprankstipranks
Trending News
More News >
Immunovant (IMVT)
NASDAQ:IMVT
US Market

Immunovant (IMVT) Income Statement

Compare
919 Followers

Immunovant Income Statement

Last quarter (Q2 2026), Immunovant's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q2, Immunovant's net income was $-126.50M. See Immunovant’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Dec 24Dec 23Dec 22Dec 21
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Operating Expenses
$ 438.15M$ 270.21M$ 208.28M$ 156.03M$ 108.12M
Depreciation and Amortization
$ 377.00K$ 231.00K$ 193.00K$ 126.00K$ 65.00K
EBITDA
$ -437.77M$ -269.98M$ -208.08M$ -155.91M$ -108.05M
Operating Income
$ -438.15M$ -270.21M$ -208.28M$ -156.03M$ -108.12M
Other Income/Expenses
$ 25.20M$ 11.44M$ -2.67M$ -781.00K$ 328.00K
Pretax Income
$ -412.95M$ -258.77M$ -210.95M$ -156.81M$ -107.79M
Net Income
$ -413.84M$ -259.34M$ -210.96M$ -156.73M$ -107.43M
Per Share Metrics
Basic EPS
$ -2.73$ -1.88$ -1.71$ -1.43$ -1.22
Diluted EPS
$ -2.73$ -1.88$ -1.71$ -1.43$ -1.22
Weighted Average Shares Outstanding
151.57M 138.10M 123.08M 109.68M 87.76M
Weighted Average Shares Outstanding (Diluted)
151.57M 138.10M 123.08M 109.68M 87.76M
Currency in USD

Immunovant Earnings and Revenue History